In summary, IHC showed that the expression of prognostic, tumor progression, stem‐cell, and breast‐specific markers does not show major differences between ERBB2‐amplified and ERBB2‐unamplified invasive lobular carcinomas. This evidence concerns the gene ERBB2 and invasive lobular breast carcinoma.